VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

"The medication's going to be 50 percent of your journey, and the other 50 percent is still what you choose to eat and the ...